Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)

NCT00092716 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

655

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: MK0653, ezetimibe / Duration of Treatment: 28 weeks
DRUG: Comparator: atorvastatin / Duration of Treatment: 28 weeks

Sponsor

Organon and Co